tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ELDN Stock Latest News

These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
Stock Analysis & IdeasThese 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
7d ago
ABOS
ELDN
Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances
PremiumCompany Announcements
Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances
27d ago
ELDN
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
PremiumPress Releases
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28d ago
ELDN
Eledon Pharmaceuticals reports Q4 EPS (32c), consensus (39c)
PremiumThe Fly
Eledon Pharmaceuticals reports Q4 EPS (32c), consensus (39c)
28d ago
ELDN
Is ELDN a Buy, Before Earnings?
PremiumPre-Earnings
Is ELDN a Buy, Before Earnings?
1M ago
ELDN
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
PremiumPress ReleasesEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
1M ago
ELDN
Eledon announces use of tegoprubart in transplant of genetically modified kidney
PremiumThe Fly
Eledon announces use of tegoprubart in transplant of genetically modified kidney
1M ago
ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
PremiumPress Releases
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
1M ago
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
ELDN
Eledon Pharmaceuticals announces anticipated 2024 milestones
PremiumThe Fly
Eledon Pharmaceuticals announces anticipated 2024 milestones
4M ago
ELDN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
PremiumPress Releases
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
4M ago
ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5M ago
ELDN
Eledon Pharmaceuticals to Present at Noble Capital Markets’ Emerging Growth Equity Conference
PremiumPress ReleasesEledon Pharmaceuticals to Present at Noble Capital Markets’ Emerging Growth Equity Conference
5M ago
ELDN
Eledon Pharmaceuticals reports Q3 EPS (35c), consensus (50c)
PremiumThe Fly
Eledon Pharmaceuticals reports Q3 EPS (35c), consensus (50c)
6M ago
ELDN
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
PremiumPress Releases
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
6M ago
ELDN
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
PremiumPress Releases
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
6M ago
ELDN
Eledon Pharmaceuticals reports updated data from Phase 1b trial of tegoprubart
PremiumThe Fly
Eledon Pharmaceuticals reports updated data from Phase 1b trial of tegoprubart
6M ago
ELDN
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
PremiumPress Releases
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
6M ago
ELDN
Eledon Pharmaceuticals price target lowered to $13 from $25 at H.C. Wainwright
PremiumThe Fly
Eledon Pharmaceuticals price target lowered to $13 from $25 at H.C. Wainwright
6M ago
ELDN
Eledon Pharmaceuticals appoints Katz as CMO
PremiumThe FlyEledon Pharmaceuticals appoints Katz as CMO
6M ago
ELDN
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
PremiumPress Releases
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
6M ago
ELDN
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
PremiumPress Releases
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
7M ago
ELDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >